On April 20, 2026 Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, reported it has scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) for mid-May 2026 to seek feedback on proposed protocol amendments to its ongoing Phase 2 HARMONIC clinical trial evaluating LP-300. The amendments are grounded in emerging clinical data demonstrating a meaningful and consistent progression-free survival signal in patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer (NSCLC) who have progressed following any TKI-based treatment (including osimertinib) — a population carrying a particularly poor prognosis and limited remaining therapeutic options. Lantern is seeking the FDA’s scientific guidance to sharpen the trial design around the patients most likely to benefit, and to pursue the most rigorous and efficient development path possible.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Emerging Clinical Evidence: A Consistent and Coherent Signal
Preliminary clinical data from the HARMONIC trial, with a data cutoff of April 13, 2026, have revealed a differentiated and consistent progression-free survival profile for LP-300 in patients harboring the EGFR Exon 21 L858R mutation — accounting for approximately 40% of all EGFR-mutant NSCLC cases globally, and a subgroup with a notably inferior prognosis following frontline TKI (including osimertinib) therapy compared with Exon 19 deletion patients. Among the 16 L858R-mutant patients enrolled in HARMONIC, LP-300 in combination with carboplatin and pemetrexed demonstrated:
8.3 mo
mPFS — L858R Patients
n=16 | 95% CI: 6.2–NC
86% / 43%
Clinical Benefit Rate / ORR
Safety Lead-In Cohort (US)
HR 0.37
L858R vs. Non-L858R
95% CI: 0.15–0.89
~$4B+
Annual Market Opportunity
L858R-enriched never-smoker NSCLC
These outcomes were observed in patients who had already progressed on tyrosine kinase inhibitor (TKI) therapy — a setting where prognosis is particularly challenging and where treatment tolerability is a critical consideration. The upper confidence interval for mPFS (median progression-free survival) for the L858R patient group remains not calculable at the time of analysis, suggesting that a meaningful proportion of patients may be achieving disease control that extends substantially beyond the reported median. The Hazard Ratio (HR) observations to date for the L858R patient group are also encouraging.
Independent Statistical Signal: Multivariable Analysis
To assess whether the emerging L858R efficacy signal might be explained by other patient characteristics, a multivariable Cox regression analysis was conducted incorporating race, gender, and TP53 mutation status. The L858R mutation remained a statistically significant independent predictor of progression-free survival across all models tested:
After adjusting for race and gender: HR 0.36 (95% CI: 0.15–0.90, p=0.028) — no significant associations were observed for race or gender alone
After incorporating TP53 mutation status: HR 0.23 (95% CI: 0.06–0.91, p=0.036) — L858R effect remained significant
These analyses are exploratory and based on a small patient cohort. Lantern plans to support these findings with additional data from the ongoing HARMONIC trial as enrollment and patient monitoring continues.
Durable Clinical Benefit: Depth and Persistence of Response
Beyond the overall L858R progression-free survival signal, exploratory analyses from the HARMONIC trial reveal several findings that further support the depth and durability of LP-300’s activity in this patient population.
Dose-Duration Signal: More Cycles, Better Outcomes
Among L858R patients in HARMONIC, those who completed 6 doses or cycles of LP-300 demonstrated a higher median PFS than the overall L858R cohort:
L858R patients completing 6 cycles of LP-300 showed a mPFS = 8.9 months (n=9, 3 patients had not yet progressed at the time of analysis)
Comparable safety profiles were observed across patients receiving 4 or 6 cycles, with no evidence of increased adverse events with longer treatment duration
This dose-duration trend is consistent with LP-300’s kinase inhibitory mechanism of action and provides supporting scientific rationale for the proposed extension of maximum treatment cycles from 6 to 8. These data are exploratory and based on small patient numbers; Lantern expects to further characterize this relationship as the trial continues.
Heavily Pretreated Patients: A Notable Signal in a Difficult Setting
Among the subset of L858R patients who had received two prior lines of systemic therapy — a particularly challenging population to treat — an encouraging preliminary signal was observed:
L858R patients with 2 prior systemic therapies: mPFS = 13.5 months (n=5; 3 patients had not yet progressed at the time of analysis)
One patient in this cohort achieved a durable complete response in target lesions, with survival continuing beyond two years. Notably, this patient’s response deepened over time, progressing from an initial partial response to a confirmed complete response — a pattern consistent with an ongoing and evolving treatment effect.
These data represent a very small patient subset and should be interpreted with appropriate caution. Individual patient outcomes may not be representative of the broader population. These findings are hypothesis-generating and will require confirmation in larger cohorts.
Why L858R — and Why Does It Matter?
The Scientific Rationale: Why LP-300 May Be Uniquely Suited to L858R
The L858R substitution replaces leucine — a hydrophobic amino acid — with positively charged arginine, disrupting the hydrophobic interactions that normally stabilize the EGFR kinase domain in its inactive conformation. The result is a receptor that preferentially adopts the active state. Critically, however, unlike Exon 19 deletion mutants — where the shortened αC-helix locks the receptor into a stable, monomer-capable active orientation — L858R tumors still require receptor dimerization to complete oncogenic activation and transformation.
This significant mechanistic distinction represents the structural basis for L858R’s unique vulnerability to dimerization interference. LP-300 is a disulfide-active small molecule whose metabolites, generated in the pericellular space, form covalent adducts with exposed cysteine residues on target proteins. The EGFR extracellular domain contains 50 cysteine residues forming 25 disulfide bonds — a structurally dense region that includes the dimerization arm through which EGFR receptors make receptor-to-receptor contact during the dimerization process. LP-300’s covalent activity at this extracellular interface provides a plausible mechanistic basis for disrupting dimerization itself, independent of the intracellular ATP-binding pocket where all currently approved EGFR inhibitors act.
These observations offer a coherent scientific hypothesis for the selectivity observed in the HARMONIC study: L858R tumors uniquely require dimerization for activation; LP-300’s covalent mechanism operates at the extracellular interface where that dimerization occurs; and the consequent attenuation of dimerization-driven signaling would be expected to selectively disadvantage L858R tumors in a manner that Exon 19 deletion tumors — which activate independently of dimerization — would not experience.
Lantern acknowledges this remains a mechanistic hypothesis requiring further experimental validation. The Company intends to incorporate mechanistic and advanced liquid biopsy studies within the amended HARMONIC protocol to further characterize this relationship as the trial advances.
Three Proposed Protocol Amendments
The following protocol amendments are being proposed to the FDA, each supported by clinical evidence and by the rapidly evolving treatment landscape for TKI-refractory NSCLC. Lantern is seeking FDA feedback and concurrence on these proposed amendments as part of the mid-May Type C meeting.
Focus Future Trial Enrollment to EGFR Exon 21 L858R Patients. Exploratory analysis from HARMONIC demonstrates that this mutation-defined subgroup derives a meaningfully greater and more consistent benefit from the LP-300 triplet regimen compared with other EGFR-mutant patients enrolled in the trial, including those with Exon 19 deletions. A multivariable Cox regression analysis confirms that L858R mutation status is an independent predictor of progression-free survival, even after adjusting for potential confounders. This supports a biomarker-driven enrollment strategy consistent with contemporary precision oncology trial design.
Convert to a Phase 2 Single-Arm Simon Two-Stage Study Design. The rapid global adoption of more recently approved combination regimens for TKI-refractory EGFR mutant NSCLC has made continued randomization to the control arm — carboplatin and pemetrexed alone — increasingly untenable both scientifically and operationally.
Increase LP-300 Treatment Cycles from 6 to 8. Exploratory data from HARMONIC indicate that L858R patients completing 6 cycles of LP-300 regimen demonstrated an mPFS of 8.9 months — higher than the overall L858R cohort median — with a comparable safety profile to those completing fewer cycles. This dose-duration relationship is consistent with LP-300’s kinase inhibitory mechanism of action. Historical safety data from prior LP-300 clinical trials also confirms that up to eight doses administered at the current dose level using the current dosing interval did not alter the established safety profile of the drug.
A Substantially Cleaner Tolerability Profile
LP-300 adds no new or clinically significant toxicity to the carboplatin and pemetrexed chemotherapy backbone. When the HARMONIC safety data to date is reviewed alongside published safety data from recently approved combination regimens in the TKI-refractory NSCLC setting, the contrast in treatment burden is clinically striking. The following comparison is based on available published data and reflects a review of LP-300’s safety profile versus a reference regimen from a larger randomized trial in a comparable, though not identical, patient population (Passaro et al., Annals of Oncology, 2024).
Lantern Pharma emphasizes that cross-trial safety comparisons should be interpreted with caution given potential differences in patient populations, study design, and data collection.
The select highlights in the table below summarize pertinent safety observations (>20%) regarding Treatment-Emergent Adverse Events (TEAE) that were determined to be Treatment Related Adverse Events (TRAE). A Treatment-Emergent Adverse Event in clinical trials is an unfavorable medical occurrence that starts or worsens in intensity or frequency after the first dose of study treatment.
Adverse Event Parameter
LP-300 + Carbo/Pem (N=31)
Reference Regimen* (N=130)
Treatment-Related SAE
1 (3%)
30 (23%)
Rash (TRAE)
2 (7%)
56 (43%)
Paronychia (TRAE)
0 (0%)
47 (36%)
*Reference regimen data: Passaro A, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024;35(1):77–90. Direct comparisons between trials should be made with caution given differences in patient populations, study design, and enrollment criteria.
For patients who have already navigated prior lines of therapy, treatment burden and quality of life are not secondary considerations. The ability to deliver comparable clinical activity with a substantially cleaner tolerability profile represents a meaningful point of differentiation in a therapeutic setting that has historically been associated with significant treatment-related morbidity.
Addressing a Large and Growing Unmet Need in EGFR-Mutant Lung Cancer
EGFR-mutant non-small cell lung cancer is one of the largest molecularly defined oncology markets globally, with approximately 350,000 new cases diagnosed annually worldwide. The EGFR Exon 21 L858R mutation — the subgroup demonstrating the most consistent observed benefit to date from LP-300 in HARMONIC — accounts for approximately 40% of all EGFR-mutant NSCLC cases, representing an estimated 90,000 to 100,000 patients per year.
The commercial significance of this population is growing. As osimertinib has become the established frontline standard of care globally, a substantial and increasing number of patients are completing first-line treatment and entering the post-TKI setting — the precise setting where HARMONIC data point to LP-300’s greatest potential clinical activity. The L858R subgroup carries a particularly poor prognosis following osimertinib failure, and existing approved options in this setting are associated with significant tolerability challenges that may limit real-world use and patient quality of life.
The market opportunity is further amplified by geography. The L858R mutation is disproportionately represented among never-smokers, who account for 35 to 40% of all NSCLC cases in Asia compared with approximately 15 to 17% in the United States and Europe. Lantern is evaluating patients across clinical sites in the United States, Japan, and Taiwan, and is exploring regional and global collaboration opportunities to maximize LP-300’s commercial potential across these geographies.
The treatment of never-smokers with NSCLC represents an estimated $4 billion or more in annual market opportunity. Lantern believes LP-300’s emerging profile — combining a consistent mutation-selective efficacy signal with a substantially differentiated tolerability profile — positions it as a potentially meaningful treatment option for a patient population with significant unmet need.
Biological Refinement: The Never-Smoker and L858R Intersection
HARMONIC was originally designed to address a critically underserved population: never-smokers with TKI-refractory NSCLC, for whom no therapy has been specifically approved. The EGFR L858R mutation is substantially enriched in never-smoker populations — particularly in Asian patient cohorts where never-smokers represent 35 to 40% of all NSCLC cases. The proposed enrollment further refines this mission; it resolves the never-smoker thesis molecularly into a more precise patient definition, concentrated on the subgroup where LP-300 appears most consistently active and beneficial.
Management Commentary
"The patients participating in HARMONIC are facing a serious illness with real courage, and often with few remaining options. Their willingness to take part in this research is what makes progress possible, and it is the reason we approach this work with both urgency and humility.
The emerging data in patients with the EGFR L858R mutation — an 8.3-month progression-free survival signal in a post-TKI setting, without additional toxicity burden — is an encouraging early finding. We understand that this is preliminary data in a small patient cohort, but the signal is consistent with the biology, and it warrants a focused, disciplined development path.
Our Type C meeting with the FDA is a collaborative step in that direction. We want their input, we respect their process, and our goal is straightforward — to determine whether LP-300 can make a meaningful difference for patients who are running out of options, and to get there as efficiently as we can."
— Panna Sharma, President and Chief Executive Officer, Lantern Pharma Inc.
Collaboration and Partnership Opportunities
Lantern Pharma is actively exploring collaboration and partnering opportunities — both globally and regionally — to maximize LP-300’s commercial potential across multiple geographies. The Company’s RADR AI platform, which integrates multi-omic biomarker data with clinical outcomes, has been instrumental in confirming and better understanding the L858R signal and continues to inform patient selection strategy and combination approaches for LP-300.
About LP-300 and the HARMONIC Trial
LP-300 is an investigational agent being evaluated in Lantern Pharma’s Phase 2 HARMONIC trial in combination with carboplatin and pemetrexed in patients with advanced NSCLC who have progressed following TKI therapy. The trial includes patients across clinical sites in the United States, Japan, and Taiwan. LP-300 has not received FDA marketing approval. All clinical data referenced in this press release are preliminary and have not been source verified in their entirety; Data Cutoff: April 13, 2026.
(Press release, Lantern Pharma, APR 20, 2026, View Source;With-No-Added-Toxicity/default.aspx [SID1234664557])